Literature DB >> 27324703

Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.

Ivana Mikolasevic1, Sandra Milic2, Lidija Orlic3, Davor Stimac2, Neven Franjic2, Giovanni Targher4.   

Abstract

BACKGROUND/AIMS: We examined the relationship between controlled attenuation parameter (CAP) and liver stiffness measurements (LSM), as assessed by transient elastography (TE), and different clinical and biochemical parameters in patients with one or more components of the metabolic syndrome (MetS). The hypothesis of the study was that LSM and CAP values correlate with the number of MetS components.
METHODS: In this cross-sectional study a total of 648 consecutive patients were recruited during the years 2013-2015. Significant liver steatosis was defined as a CAP value≥238dB/m, whereas significant fibrosis was defined as an LSM value>7.0 kPa.
RESULTS: The prevalences of patients with CAP≥238dB/m and LSM>7.0 kPa were 88.3% and 16.5%, respectively. Patients with CAP≥238dB/m (n=572) had a markedly higher prevalence of the MetS and all its individual components, as well as higher levels of serum liver enzymes and uric acid compared with those with normal CAP. Moreover, CAP measurements increased progressively with the number of MetS components. Similarly, among patients with CAP≥238dB/m, those with LSM>7.0 kPa (n=103) had higher serum liver enzymes and a greater prevalence of the MetS and its individual components than those with LSM≤7.0 kPa. In multivariable regression analysis the factors independently associated with elevated CAP were the presence of the MetS (or its individual components), insulin resistance (defined by HOMA-IR score), increased serum uric acid and LSM>7 kPa. Similarly, the MetS (or its individual components), insulin resistance and increased serum uric acid levels were also independently associated with LSM>7.0 kPa.
CONCLUSIONS: Patients with one or more MetS components have a high prevalence of NAFLD and advanced liver fibrosis. LSM and CAP correlate with the number of MetS components.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Controlled attenuation parameter; Liver stiffness measurement; Metabolic syndrome; Non-alcoholic fatty liver disease; Transient elastography

Mesh:

Substances:

Year:  2016        PMID: 27324703     DOI: 10.1016/j.jdiacomp.2016.05.014

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  11 in total

Review 1.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

2.  Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome.

Authors:  Sanda Mustapic; Sead Ziga; Vladimir Matic; Tomislav Bokun; Bozo Radic; Marko Lucijanic; Srecko Marusic; Zarko Babic; Ivica Grgurevic
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-23

3.  Metabolic Characteristics of a Novel Ultrasound Quantitative Diagnostic Index for Nonalcoholic Fatty Liver Disease.

Authors:  Yin-Yin Liao; Chih-Kuang Yeh; Kuo-Chin Huang; Po-Hsiang Tsui; Kuen-Cheh Yang
Journal:  Sci Rep       Date:  2019-05-28       Impact factor: 4.379

4.  Association between Smoking and Liver Fibrosis among Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Hongjie Ou; Yaojie Fu; Wei Liao; Caixia Zheng; Xiaolu Wu
Journal:  Can J Gastroenterol Hepatol       Date:  2019-10-15

5.  Ultrasound Entropy Imaging of Nonalcoholic Fatty Liver Disease: Association with Metabolic Syndrome.

Authors:  Ying-Hsiu Lin; Yin-Yin Liao; Chih-Kuang Yeh; Kuen-Cheh Yang; Po-Hsiang Tsui
Journal:  Entropy (Basel)       Date:  2018-11-22       Impact factor: 2.524

6.  Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements.

Authors:  Ivana Mikolasevic; Goran Poropat; Tajana Filipec Kanizaj; Nadija Skenderevic; Marko Zelic; Marija Matasin; Luka Vranic; Andrea Kresovic; Goran Hauser
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-23

7.  Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement.

Authors:  Zhimin Huang; Kaka Ng; Hongyan Chen; Wanping Deng; Yanbing Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-31       Impact factor: 5.555

8.  Hyperuricemia Is Associated with Significant Liver Fibrosis in Subjects with Nonalcoholic Fatty Liver Disease, but Not in Subjects without It.

Authors:  Pei-Chia Yen; Yu-Tsung Chou; Chung-Hao Li; Zih-Jie Sun; Chih-Hsing Wu; Yin-Fan Chang; Feng-Hwa Lu; Yi-Ching Yang; Chih-Jen Chang; Jin-Shang Wu
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

Review 9.  The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider.

Authors:  Nicolás Salva-Pastor; Norberto C Chávez-Tapia; Misael Uribe; Natalia Nuño-Lámbarri
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

10.  Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements.

Authors:  Ivana Mikolasevic; Goran Hauser; Maja Mijic; Viktor Domislovic; Delfa Radic-Kristo; Zeljko Krznaric; Melanija Razov-Radas; Tajana Pavic; Marija Matasin; Tajana Filipec Kanizaj
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.